213 related articles for article (PubMed ID: 34711014)
21. Periostin expression and its supposed roles in benign and malignant thyroid nodules: an immunohistochemical study of 105 cases.
Kusafuka K; Yamashita M; Iwasaki T; Tsuchiya C; Kubota A; Hirata K; Murakami A; Muramatsu A; Arai K; Suzuki M
Diagn Pathol; 2021 Sep; 16(1):86. PubMed ID: 34563225
[TBL] [Abstract][Full Text] [Related]
22. [Comparison of CD15, galectin-3 and HBME-1 expression in follicular thyroid neoplasms].
Bogdańska M; Górnicka B; Ziarkiewicz-Wróblewska B; Koperski L; Morton M; Wasiutyński A
Endokrynol Pol; 2006; 57(4):314-9. PubMed ID: 17006830
[TBL] [Abstract][Full Text] [Related]
23. Cytological features of "noninvasive follicular thyroid neoplasm with papillary-like nuclear features" and their correlation with tumor histology.
Maletta F; Massa F; Torregrossa L; Duregon E; Casadei GP; Basolo F; Tallini G; Volante M; Nikiforov YE; Papotti M
Hum Pathol; 2016 Aug; 54():134-42. PubMed ID: 27085556
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemistry Helps to Distinguish Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features/Noninvasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma with Other Follicular Thyroid Lesions.
Chuang HW; Wang JS; Tsai JW; Hsu CT; Lin KJ
Medicina (Kaunas); 2021 Nov; 57(11):. PubMed ID: 34833464
[No Abstract] [Full Text] [Related]
25. Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China.
Song Q; Wang D; Lou Y; Li C; Fang C; He X; Li J
Diagn Pathol; 2011 Dec; 6():126. PubMed ID: 22188859
[TBL] [Abstract][Full Text] [Related]
26. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.
Mataraci EA; Ozgüven BY; Kabukçuoglu F
Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608
[TBL] [Abstract][Full Text] [Related]
27. The Role of CD56 in Thyroid Fine Needle Aspiration Cytology: A Pilot Study Performed on Liquid Based Cytology.
Bizzarro T; Martini M; Marrocco C; D'Amato D; Traini E; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM; Rossi ED
PLoS One; 2015; 10(7):e0132939. PubMed ID: 26186733
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X
J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
[TBL] [Abstract][Full Text] [Related]
29. The value of tumor markers in the diagnosis of papillary thyroid carcinoma alone and in combination.
Ma H; Xu S; Yan J; Zhang C; Qin S; Wang X; Li N
Pol J Pathol; 2014 Oct; 65(3):202-9. PubMed ID: 25372417
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
Abouhashem NS; Talaat SM
Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
[TBL] [Abstract][Full Text] [Related]
31. Thyroid tumors of uncertain malignant potential: morphologic and imunohistochemical analysis of 29 cases.
Nechifor-Boila A; Borda A; Sassolas G; Hafdi-Nejjari Z; Cătană R; Borson-Chazot F; Berger N; Decaussin-Petrucci M
Pathol Res Pract; 2015 Apr; 211(4):320-5. PubMed ID: 25595997
[TBL] [Abstract][Full Text] [Related]
32. [Expression of GADD153 in follicular tumors of thyroid and comparison with CK19, Galectin-3 and HBME-1].
Tang QS; Teng XD; Ding W; Zhou J; Yao HT; Ying LX; Xu LM
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):745-8. PubMed ID: 22336157
[TBL] [Abstract][Full Text] [Related]
33. Differential expression of galectin-3, CK19, HBME1, and Ret oncoprotein in the diagnosis of thyroid neoplasms by fine needle aspiration biopsy.
Saleh HA; Feng J; Tabassum F; Al-Zohaili O; Husain M; Giorgadze T
Cytojournal; 2009 Sep; 6():18. PubMed ID: 19826479
[TBL] [Abstract][Full Text] [Related]
34. [Usefulness of CK19, HBME-1 and galectin-3 expressions in differential diagnosis of thyroid papillary microcarcinoma from benign lesions].
Tong J; Wang Y; Da JP
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):599-604. PubMed ID: 22325220
[TBL] [Abstract][Full Text] [Related]
35. CD56 expression in benign and malignant thyroid lesions.
Muthusamy S; Azhar Sha S; Abdullah Suhaimi SN; Kassim N; Mahasin M; Mohd Saleh MF; Md Isa N
Malays J Pathol; 2018 Aug; 40(2):111-119. PubMed ID: 30173227
[TBL] [Abstract][Full Text] [Related]
36. Encapsulated follicular thyroid tumor with equivocal nuclear changes, so-called well-differentiated tumor of uncertain malignant potential: a morphological, immunohistochemical, and molecular appraisal.
Liu Z; Zhou G; Nakamura M; Koike E; Li Y; Ozaki T; Mori I; Taniguchi E; Kakudo K
Cancer Sci; 2011 Jan; 102(1):288-94. PubMed ID: 21070478
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical markers in the diagnosis of papillary thyroid carcinomas: The promising role of combined immunostaining using HBME-1 and CD56.
Nechifor-Boila A; Borda A; Sassolas G; Hafdi-Nejjari Z; Borson-Chazot F; Lifante JC; Sturm N; Lavérriere MH; Berger N; Decaussin-Petrucci M
Pathol Res Pract; 2013 Sep; 209(9):585-92. PubMed ID: 23910176
[TBL] [Abstract][Full Text] [Related]
38. Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential.
Papotti M; Rodriguez J; De Pompa R; Bartolazzi A; Rosai J
Mod Pathol; 2005 Apr; 18(4):541-6. PubMed ID: 15529186
[TBL] [Abstract][Full Text] [Related]
39. The investigation of galectin-3 in diseases of the thyroid gland.
Kovács RB; Földes J; Winkler G; Bodó M; Sápi Z
Eur J Endocrinol; 2003 Nov; 149(5):449-53. PubMed ID: 14585093
[TBL] [Abstract][Full Text] [Related]
40. Ki-67 and AgNOR proliferative markers as diagnostic adjuncts to fine needle aspiration cytology of thyroid follicular lesions.
Mehrotra A; Goel MM; Singh K
Anal Quant Cytol Histol; 2002 Aug; 24(4):205-11. PubMed ID: 12199321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
